Synthesis of Danuglipron: Development of a Scalable Alkylation and Chemoselective Hydrolysis Sequence

The target compound danuglipron belongs to a family of glucagon-like peptide-1 receptor agonist (GLP-1RA) candidates identified in the Pfizer laboratories for the treatment of type 2 diabetes mellitus and obesity. This article describes a development approach providing a data-centric, holistic methodology toward process design. The approach starts with rapid collection and generation of fundamental data through high-throughput experimentation (HTE), followed by lead evaluation, narrowing process options, and concluding with lead process confirmation. This systematic strategy identifies the most efficient process options, anticipates process sensitivities, removes unconscious bias in decision making, leading to fewer process iterations, and identifies an optimal process. By adopting this approach to danuglipron, a new 5-step process was developed, removing two unnecessary process steps, increasing the yield from 34 to 64%, and reducing PMI from 231 to 73 kg/kgA while being scaled at multiple facilities to generate metric tons of clinical-grade danuglipron.

Authors

Institutions

Publication Details

Journal
Organic Process Research & Development
Published
2026-07-17
DOI
https://doi.org/10.1021/acs.oprd.6c00144
Primary Topic
Synthetic Organic Chemistry Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Synthesis of Danuglipron: Development of a Scalable Alkylation and Chemoselective Hydrolysis Sequence

Andrew Derrick, Dylan Pedro, Angela L. A. Puchlopek-Dermenci, Taegyo Lee et al.
Organic Process Research & Development
Synthetic Organic Chemistry Methods
article

Synthesis of Danuglipron: Development of a Scalable Alkylation and Chemoselective Hydrolysis Sequence

Andrew Derrick, Dylan Pedro, Angela L. A. Puchlopek-Dermenci, Taegyo Lee, Ijaz Ahmed, Václav Svoboda, Aining Wang, Aaron F. Baldwin, Giselle P. Reyes, Patrick O’Neill, Steven J. Fussell, Steven J. R. Twiddle, Adam E. S. Gymer, Adam West, Gerald A. Weisenburger, David F. Fernández, Russell F. Algera, Ursula Sheridan, Jian Li, Nga M. Do, Brian P. Jones, Nahian Khan, Lesly Mejia, Danielle Green, James Rellegue, Daniel Laity, Ian Moses, Chase Mack, Jordan Willie, Sarah Karasik
article en

Abstract

The target compound danuglipron belongs to a family of glucagon-like peptide-1 receptor agonist (GLP-1RA) candidates identified in the Pfizer laboratories for the treatment of type 2 diabetes mellitus and obesity. This article describes a development approach providing a data-centric, holistic methodology toward process design. The approach starts with rapid collection and generation of fundamental data through high-throughput experimentation (HTE), followed by lead evaluation, narrowing process options, and concluding with lead process confirmation. This systematic strategy identifies the most efficient process options, anticipates process sensitivities, removes unconscious bias in decision making, leading to fewer process iterations, and identifies an optimal process. By adopting this approach to danuglipron, a new 5-step process was developed, removing two unnecessary process steps, increasing the yield from 34 to 64%, and reducing PMI from 231 to 73 kg/kgA while being scaled at multiple facilities to generate metric tons of clinical-grade danuglipron.

Organic Process Research & Development
Pfizer (United States) (US), Pfizer (United Kingdom) (GB), Pfizer (Ireland) (IE)
Openalex Percentile: Top 15%
Synthetic Organic Chemistry Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.